Search

Search Results

• 

  Antibodies to extractable nuclear antigens (ENAS) in systemic lupus erythematosus patients: correlations with clinical manifestations and disease activity

  Y. Emad, T. Gheita, H. Darweesh, P. Klooster, R. Gamal, H. Fathi, N. El-Shaarawy, M. Gamil, M. Hawass, R.M. El-Refai, H. Al-Hanafi, S. Abd-Ellatif, A. Ismail, J. Rasker

  85-91

  06-07-2018

  https://doi.org/10.4081/reumatismo.2018.1027

  2898

  PDF: 1630

• PO:12:179 | Cardiovascular outcomes of treat-to-target urate-lowering therapy in gout: emulated target trials Edoardo Cipolletta¹, Davide Rozza², Abhishek Abhishek³ | ¹Azienda Ospedaliero Universitaria delle Marche, Ancona, Italy; ²Società Italiana di Reumatologia, Milano, Italy; ³University of Nottingham Nottingham, United Kingdom

  Società Italiana di Reumatologia

  18-03-2026

  https://doi.org/10.4081/reumatismo.2025.2314

  33
• 

  Pain in rheumatic diseases: how relevant is it?

  P. Sarzi-Puttini, F. Atzeni, F. Salaffi

  1-3

  06-06-2014

  https://doi.org/10.4081/reumatismo.2014.757

  2267

  PDF: 1263

• PO:16:236 | Achieving a low disease activity state with a corticosteroid dose of 5 mg or less: observational study with anifrolumab in patients with systemic lupus erythematosus in Italy Alessandra Bortoluzzi¹, Fulvia Ceccarelli², Fabio Leo³, Paola Roccatagliata³, Chiara Tani⁴, Margherita Zen⁵ | ¹Azienda Ospedaliera Universitaria Sant' Anna di Cona, Università di Ferrara Italy; ²Unità di Reumatologia, Università Sapienza Roma Italy; ³AstraZeneca S.p.a. Milano Italy; ⁴Università di Pisa e Azienda Ospedaliero Universitaria Pisana, Pisa Italy; ⁵Dipartimento di Medicina DIMED , Divisione di Reumatologia, Università di Padova, Italy

  Società Italiana di Reumatologia

  25-11-2025

  https://doi.org/10.4081/reumatismo.2025.2163

  110

• PO:08:113 | Shaping rheumatoid arthritis treatment: clinical and demographic drivers of tsDMARDs versus bDMARDs prescription post-EMA pronouncement on JAK inhibitors - insights from the AMBI-RA study Riccardo Bertola¹, Beatrice Maranini¹, Carlo Garaffoni¹, Maria Pozzuto¹, Anna Laura Riva Cambrino¹, Alessandro Spinelli¹, Letizia Mamprin¹, Federico Agostini¹, Martina Di Nunzio¹, Marcello Govoni¹, Alessandra Bortoluzzi¹, Ettore Silvagni¹ | ¹Rheumatology Unit, Department of Medical Sciences, University of Ferrara and Azienda Ospedaliero-Universitaria S. Anna, Italy

  Società Italiana di Reumatologia

  25-11-2025

  https://doi.org/10.4081/reumatismo.2025.2139

  151

• PO:06:083 | Clinical characteristics and outcomes of late- and young-onset rheumatoid arthritis in relation to autoantibody status Federica Sabatelli^1|2, Ludovico De Stefano^1|2, Clelia Zampaglione^1|2, Lisa Bergianti^1|2, Blerina Xoxi^1|2, Antonio Manzo^1|2, Carlomaurizio Montecucco^1|2, Serena Bugatti^1|2. | ¹Department of Internal Medicine and Therapeutics, University of Pavia, Pavia; ²Division of Rheumatology, IRCCS Policlinico San Matteo Foundation, Pavia, Italy.

  Società Italiana di Reumatologia

  25-11-2025

  https://doi.org/10.4081/reumatismo.2025.2015

  115

• How much does an antiinflammatory treatment cost?

  D. Gatti, O. Viapiana, G. Colombo, S. Adami

  248-252

  https://doi.org/10.4081/reumatismo.2010.248

  1365

  PDF: 741

• PO:07:108 | Achievement of Treatment Targets and Maintenance of Response with Upadacitinib in Patients with Moderate-to-Severe Rheumatoid Arthritis in a Real-world Setting: Final 2-year Outcomes from the UPHOLD Study Enrico Marchetta¹, Andrew Östör^2|8, Eugen Feist³, Prodromos Sidiropoulos⁴, Jérôme Avouac⁵, Martin Rebella^6|7, Rajaie Namas⁹, Erin Mcdearmon Blondell¹⁰, Ivan Lagunes¹⁰, Tianming Gao¹⁰, Tim Shaw¹⁰, Suzan Attar¹¹ | ¹AbbVie Srl Roma, Italy; ²Monash University and Emeritus Research, Melbourne, Victoria, Melbourne, Australia; ³Helios Department of Rheumatology and Clinical Immunology, Vogelsang-Gommern, Vogelsang Gommern, Germany; ⁴Faculty of Medicine, University of Crete, Heraklion, Heraklion, Greece; ⁵Service de Rhumatologie, Hôpital Cochin, AP HP Centre Université Paris Cité, Parigi, France; ⁶Departamento de Medicina, Facultad de Medicina, Universidad de la República, Montevideo, Montevideo, Uruguay; ⁷Unidad de Enfermedades Autoinmunes Sistémicas, MUCAM, Montevideo, Montevideo, Uruguay; ⁸Australian National University, Camberra, Australia; ⁹Medical Subspecialties Institute, Division of Rheumatology, Cleveland Clinic Abu Dhabi, United Arab Emirates; ¹⁰AbbVie Inc., North Chicago, Illinois, United States of America Chicago, USA; ¹¹King Abdulaziz University, Jeddah, Saudi Arabia

  Società Italiana di Reumatologia

  18-03-2026

  https://doi.org/10.4081/reumatismo.2025.2306

  16

• PO:07:111 | Worsening of patient-reported outcomes is an early predictor of disease flare in patients with rheumatoid arthritis in course of treatment with conventional synthetic disease modifying anti-rheumatic drugs Ludovico De Stefano^1|2, Federica Sabatelli^1|2, Clelia Zampaglione^1|2, Blerina Xoxi², Antonio Manzo^1|2, Carlomaurizio Montecucco^1|2, Serena Bugatti^1|2. | ¹Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy; ²Division of Rheumatology, IRCCS Policlinico San Matteo Foundation, Pavia, Italy.

  Società Italiana di Reumatologia

  25-11-2025

  https://doi.org/10.4081/reumatismo.2025.2022

  135

• PO:14:198 | Temporal Trends in LLDAS and DORIS Achievement in SLE: Impact of Evolving International Recommendations Laura Coladonato¹, Marco Fornaro¹, Angelica Napoletano¹, Daniele Catamerò¹, Giuseppe Lopalco¹, Florenzo Iannone¹ | ¹UOC Reumatologia, Policlinico di Bari, DiMePre-J Bari, Italy

  Società Italiana di Reumatologia

  18-03-2026

  https://doi.org/10.4081/reumatismo.2025.2321

  21